Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Hsu

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal of Women'S Health (2002)|May 15, 2015
The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative surveyKathleen Lang, Ivy M Alexander, James Simon, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Current Therapeutic Research, Clinical and Experimental|September 28, 2020
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic ArthritisDafna D Gladman, Ana-Maria Orbai, Juan Gomez-Reino, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patientsAnn Hsu, Jeffrey Isaacson, Scott Brun, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|November 30, 2007
Zebrafish ae2.2 encodes a second slc4a2 anion exchangerBoris E Shmukler, Jeffrey S Clark, Ann Hsu, et al.
Patient Preference and Adherence|July 2, 2020
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country StudyDaniel Aletaha, M Elaine Husni, Joseph F Merola, et al.
The Lancet. Rheumatology|January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension studyPeter Nash, Laura C Coates, Dona Fleishaker, et al.
Journal of the Neurological Sciences|January 30, 2017
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's diseaseJames Tetrud, Paul Nausieda, David Kreitzman, et al.
Blood Cells, Molecules & Diseases|December 14, 2019
Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermediaBoris E Shmukler, Alicia Rivera, Parul Bhargava, et al.
Dermatology and Therapy|December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal of Women'S Health (2002)|May 15, 2015
The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative surveyKathleen Lang, Ivy M Alexander, James Simon, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Current Therapeutic Research, Clinical and Experimental|September 28, 2020
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic ArthritisDafna D Gladman, Ana-Maria Orbai, Juan Gomez-Reino, et al.
Antimicrobial Agents and Chemotherapy|December 25, 2002
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patientsAnn Hsu, Jeffrey Isaacson, Scott Brun, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|November 30, 2007
Zebrafish ae2.2 encodes a second slc4a2 anion exchangerBoris E Shmukler, Jeffrey S Clark, Ann Hsu, et al.
Patient Preference and Adherence|July 2, 2020
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country StudyDaniel Aletaha, M Elaine Husni, Joseph F Merola, et al.
The Lancet. Rheumatology|January 27, 2024
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension studyPeter Nash, Laura C Coates, Dona Fleishaker, et al.
Journal of the Neurological Sciences|January 30, 2017
Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's diseaseJames Tetrud, Paul Nausieda, David Kreitzman, et al.
Blood Cells, Molecules & Diseases|December 14, 2019
Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermediaBoris E Shmukler, Alicia Rivera, Parul Bhargava, et al.
Dermatology and Therapy|December 31, 2020
Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe ADRebecca Hall, Mark G Lebwohl, Andrew G Bushmakin, et al.
Pageof 7